The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib

被引:0
|
作者
Omran, Mervat M. [1 ]
Ibrahim, Amel B. [2 ]
Abdelfattah, Raafat [3 ]
Moussa, Heba S. [4 ]
Shouman, Samia A. [1 ]
Hamza, Marwa S. [5 ]
机构
[1] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Kasr Al Eini St, Cairo 11796, Egypt
[2] Zawia Univ, Fac Med, Dept Pharmacol, Az Zawiyah, Libya
[3] Cairo Univ, NCI, Med Oncol Dept, Cairo, Egypt
[4] Cairo Univ, NCI, Clin Pathol Dept, Cairo, Egypt
[5] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, El Sherouk City, Cairo, Egypt
关键词
Imatinib mesylate; CML; adherence; trough; peak; CHRONIC MYELOGENOUS LEUKEMIA; CYTOGENETIC RESPONSES; TYROSINE KINASE; BLAST CRISIS; THERAPY; NONADHERENCE; OUTCOMES;
D O I
10.1080/10428194.2024.2403671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge, motivation, and adherence to IM therapy, and their collective impact on clinical outcomes. A prospective, observational study was conducted with 101 CML patients. The 6-Item Morisky Medication Adherence Scale (MMAS-6) was used to assess adherence, motivation, and knowledge levels. The study found that high motivation was significantly associated with lower BCR-ABL expression (p = 0.025). Patients with high knowledge and motivation had a 71% favorable response rate, compared to 0% in those with low knowledge and motivation (p = 0.01). As conclusion both patient motivation and knowledge are crucial for favorable treatment outcomes in CML. High levels of both significantly correlate with better clinical responses. Tailored interventions to enhance patient knowledge and motivation are essential.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
  • [21] PREGNANCY AMONG THE PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON IMATINIB THERAPY
    Chelysheva, E. Y.
    Turkina, A. G.
    Gusarova, G. A.
    Kolosheinova, T. I.
    Sokolova, M. A.
    Khoroshko, N. D.
    Pepelyaeva, V. M.
    Gavrilova, L. V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 262 - 262
  • [22] Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania
    Nasser, Ahlam
    Hussein, Ally
    Chamba, Clara
    Yonazi, Mbonea
    Mushi, Rosemary
    Schuh, Anna
    Luzzatto, Lucio
    BLOOD ADVANCES, 2021, 5 (05) : 1403 - 1411
  • [23] Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
    Lee, Sung-Eun
    Choi, Soo Young
    Bang, Ju-Hee
    Kim, Soo-Hyun
    Jang, Eun-jung
    Byeun, Ji-Young
    Park, Jin-Eok
    Jeon, Hye-Rim
    Oh, Yun Jeong
    Kim, Hyeoung-Joon
    Kim, Yeo-Kyeoung
    Park, Joon Seong
    Jeong, Seong Hyun
    Kim, Sung-Hyun
    Zang, Dae Young
    Oh, Sukjoong
    Koo, Dong Hoe
    Kim, Hawk
    Do, Young Rok
    Kwak, Jae-Yong
    Kim, Jeong-A
    Kim, Dae-Young
    Mun, Yeung-Chul
    Mauro, Michael J.
    Kim, Dong-Wook
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (06) : 449 - 454
  • [24] Relationship between adherence, drug level and clinical response achieved in patients with chronic myeloid leukemia on imatinib
    Omran, M. M.
    Abdelfatah, R.
    Mousa, H.
    Alieldin, N.
    Shouman, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
    Cojbasic, Irena
    Macukanovic-Golubovic, Lana
    VOJNOSANITETSKI PREGLED, 2011, 68 (11) : 911 - 916
  • [26] Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting
    Saleh, Mansoor N.
    Haislip, Sally
    Sharpe, Joyce
    Hess, Tamara
    Gilmore, James
    Jackson, James
    Sail, Kavita R.
    Ericson, Solveig G.
    Chen, Lei
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (04) : 529 - 536
  • [27] Pharmacogenetic Markers of Treatment Response of Imatinib Mesylate in Chronic Myeloid Leukemia Brazilian Patients
    Vieira, Natlia M.
    Leite, Renata
    Reginato, Fabiola
    Zandona, Marilia
    Costa, Tito Vanelli
    Fogliatto, Laura
    Linden, Rafael
    Antunes, Marina Venzon
    Capron, Arnaud
    Wallemacq, Pierre
    Wagner, Sandrine
    Mattevi, Vanessa
    Capra, Marcelo
    BLOOD, 2016, 128 (22)
  • [28] Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia
    Nekoohesh, Ladan
    Rostami, Shahrbano
    Nikbakht, Mohsen
    Mohammadi, Saeed
    Babakhani, Davood
    Alimoghaddam, Kamran
    Ghahremani, Mohammad H.
    Chahardouli, Bahram
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01): : E1 - E10
  • [29] Cytogenetic responses in chronic myeloid leukemia patients treated with imatinib mesylate
    Babameto-Laku, A.
    Mokin, V.
    Cikuli, M.
    Xhumari, P.
    CHROMOSOME RESEARCH, 2005, 13 : 158 - 158
  • [30] Ocular side effects in chronic myeloid leukemia patients treated with imatinib
    Breccia, Massimo
    Gentilini, Fabiana
    Cannella, Laura
    Latagliata, Roberto
    Carmosino, Ida
    Frustaci, Annamaria
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2008, 32 (07) : 1022 - 1025